<DOC>
	<DOCNO>NCT02191319</DOCNO>
	<brief_summary>Collecting data maintain anti-retroviral activity ( quantitative HIV RNA determination ) immunological activity ( CD4 cell ) switch protease inhibitor NNRTI Nevirapine ( Viramune® ) collect routinely observe laboratory data lipid , liver enzymes .</brief_summary>
	<brief_title>Observational Study With Antiretroviral Treated Patients Switching Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor ( NRTI ) Regimens</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Patients suffer HIV type 1 infection Patient treat antiretroviral proteaseinhibitors nonnucleoside reverse transcriptase inhibitor Patient show depression viral load limit detection ( &lt; 50 HIVRNA copies/ml ) 6 month prior visit 1 Patient male female age great equal 18 year Women willing use effective barrier method contraception duration observational study participation Patient clinically relevant laboratory finding ( e.g. , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; five time upper limit normal ( ULN ) ) Patients hypersensitive Viramune® excipients Patient able abstain treatment ketoconazole , oral contraceptive , drug affect CYP3Ametabolism Patients breastfeed Patient pregnant Patient woman use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>